LORNOXICAM DRUG PROFILE PDF

Lornoxicam is a non-steroidal anti-inflammatory drug of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It is available in oral and. Lornoxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory. Lornoxicam is a nonsteroidal anti-inflammatory drug with analgesic properties From: Profiles of Drug Substances, Excipients and Related Methodology,

Author: Tektilar Mazugis
Country: New Zealand
Language: English (Spanish)
Genre: Spiritual
Published (Last): 10 April 2005
Pages: 460
PDF File Size: 4.82 Mb
ePub File Size: 16.52 Mb
ISBN: 235-5-87665-643-7
Downloads: 13017
Price: Free* [*Free Regsitration Required]
Uploader: Togar

Iobenguane sulfate I Lornoxicam may decrease the excretion rate of Iobenguane sulfate I which could result in a higher serum level. Azilsartan medoxomil The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Lornoxicam.

Gatifloxacin Lornoxicam may increase the neuroexcitatory activities of Gatifloxacin. Nonsteroidal anti-inflammatory drugs Thienothiazines Pyridines Chloroarenes Carboxamides. Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.

Alprenolol Lornoxicam may decrease the antihypertensive activities of Alprenolol. Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam. Didanosine Lornoxicam may decrease the excretion rate of Didanosine which could result in a higher serum level. Fluperolone The risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Lornoxicam.

Gentamicin C1a The risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Gentamicin C1a. Dibekacin The risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Dibekacin.

Gliclazide The protein binding of Gliclazide can be decreased when combined with Lornoxicam. Diethyl ether The risk or severity of hypertension can be increased when Lornoxicam is combined with Diethyl ether. Lovastatin The metabolism of Lornoxicam can be decreased when combined with Lovastatin.

Chlorpropamide The protein binding of Chlorpropamide can be decreased when combined with Lornoxicam. Gemifloxacin Lornoxicam may increase the neuroexcitatory activities of Gemifloxacin. Fosinoprilat The risk or severity of renal failure, hyperkalemia, and hypertension can be profipe when Lornoxicam is combined with Fosinoprilat.

  3RW34 MANUAL PDF

Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Lornoxicam.

Visual disturbance, ringing in ear and sensitivity to light.

Lornoxicam | C13H10ClN3O4S2 – PubChem

Gemfibrozil The metabolism of Lornoxicam can be decreased when combined with Gemfibrozil. Chloral hydrate Lornoxicam may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.

Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Lornoxicam. Clorindione The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Clorindione.

Chromium nicotinate Lornoxicam may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Flunoxaprofen The risk or severity of adverse effects lornoxicaam be increased when Lornoxicam is combined with Flunoxaprofen.

Amibegron The risk or severity of hypertension can be increased when Amibegron is combined with Lornoxicam. Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Lornoxicam.

Dolasetron The metabolism of Lornoxicam can be decreased when combined with Dolasetron. Frug The risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Lornoxicam.

Isoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Isoxicam.

Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Lornoxicam. Clopidogrel The metabolism of Lornoxicam can be decreased when combined with Clopidogrel. Barnidipine The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Barnidipine. This page was last edited on 14 Julyat Acetohexamide The protein binding of Acetohexamide can be decreased when combined with Lornoxicam.

Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Lornoxicam. Amitriptyline Lornoxican may decrease the excretion rate of Amitriptyline which could result in a higher serum level.

  EL OGRO FILANTROPICO PDF

Lornoxicam information from DrugsUpdate

Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Lornoxicam. Canrenone The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Canrenone. Guanoxabenz The therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Lornoxicam. Storage Information Not Available. Flunarizine The risk or severity of hyperkalemia can be increased when Flunarizine is combined with Lornoxicam.

Deoxyepinephrine The risk or severity of hypertension can be increased when Lornoxicam is combined with Deoxyepinephrine. Lansoprazole The metabolism of Lornoxicam can be increased when combined with Lansoprazole. Cariprazine The risk or severity of hypertension can be increased when Cariprazine is lornodicam with Lornoxicam. Peofile Lornoxicam may decrease the antihypertensive activities of Esatenolol. Dexmedetomidine Lornoxicam may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.

Amoxicillin Lornoxicam may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Imidapril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Imidapril.

There was a problem providing the content you requested

IUPAC name 3 E chloro[hydroxy pyridinylamino methylene]methyl-2,3-dihydro-4 H -thieno[2,3- e ][1,2]thiazinone 1,1-dioxide. Dibenzepin The risk or severity of hypertension can be increased when Lornoxicam is combined with Dibenzepin.

Osteoarthritis can affect any joint of the body. Buflomedil The risk or severity of hypertension can be increased when Lornoxicam is combined with Buflomedil. Labetalol Lornoxicam may decrease the antihypertensive activities of Labetalol. Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Lornoxicam.